Skip to content

SAMHD1 Research — 2026-07 Monthly Synthesis

Auto-generated synthesis of the weekly digests for 2026-07. Model: claude-sonnet-5.

The month in one paragraph

July's literature reinforced every arm of the SAMHD1 A565T mechanistic model without directly studying the variant itself. Two clinical case reports provided the month's strongest translational signal: JAK inhibition normalized interferon signatures in both ADAR1-related and PNPT1-related interferonopathies, reinforcing ruxolitinib/tofacitinib as a class-level therapeutic strategy for nucleic-acid-sensing disorders. A dense cluster of mechanistic papers—spanning oncology, cardiology, hepatology, and toxicology—converged on the same core circuitry relevant to the family's disease: VDAC1/mPTP-mediated mtDNA release, cGAS-STING activation, and downstream NLRP3/IL-1β signaling, several using the same pharmacologic tools (VBIT-4, MCC950) implicated in the SAMHD1 model. Negative-feedback regulators of STING (TAX1BP1, EXOC5, ANXA2) emerged as a notable new therapeutic-node theme. On the gene-correction front, two prime-editing engineering papers advanced generalizable efficiency/specificity platforms potentially applicable to future SAMHD1 A565T correction, though neither is disease- or cell-type-specific yet.

Most important papers

  • JAK inhibition reverses IFN signature in ADAR1-AGS — Ruxolitinib+dexamethasone down-regulated CGAS, SAMHD1, ISG15, and JAK1 by single-cell RNA-seq, offering the closest available clinical precedent for JAK-inhibitor efficacy against the exact ISG module dysregulated in A565T carriers (interferon arm; therapy).

  • JAK inhibition in PNPT1 mitochondrial interferonopathy — Tofacitinib normalized IFN signature and clinical markers (dystonia, lactate, transaminases) in a disorder driven by mt-dsRNA cytosolic leakage, mechanistically mirroring the VDAC1→mtDNA→cGAS-STING→JAK-STAT axis proposed for SAMHD1 haploinsufficiency (mitochondrial + interferon arms; therapy).

  • STAT2 R148 founder variant responds to high-dose JAK inhibition — A distinct IFN-I overproduction disorder (disrupted USP18 feedback) again validated JAK inhibitors as disease-modifying, strengthening the rationale for ruxolitinib-class agents across interferonopathies (interferon arm; therapy).

  • cGAS/HDAC dual inhibitor effective in a murine AGS model — A novel small-molecule class directly targeting the cGAS-STING loop, with in vivo AGS efficacy, represents a plausible future pharmacologic option beyond JAK inhibition (interferon arm; therapy).

  • VDAC1 oligomerization → mtDNA release → NLRP3 pyroptosis (copper hepatocyte model) and parallel papers (osteosarcoma SLC30A9-cGAS-STING, CMPK2-driven NLRP3 in sepsis) — Collectively confirm that the VDAC1/mtDNA/cGAS-STING/NLRP3